Sofinnova launches healthcare crossover fund

Paris-based Sofinnova Partners has launched a new €275 million fund to expand the scope of its investments in life science to include late-stage private and public companies primarily located in Europe.

Full text available to subscribers only. Click here for information on subscribing to MedNous.